The policy advocates for federal oversight of compounding pharmacies advertising drugs that are in shortage, the prevention of artificial drug shortages and the introduction of incentives to encourage manufacturers to invest in improving product processes.
A key focus of the AMA’s policy is the shortage of semaglutide and other GLP-1s, which have faced increased demand due to aggressive advertising, particularly on social media, according to a Nov. 13 news release from the organization. The AMA is calling for the FDA, the Federal Trade Commission and other agencies to investigate these advertising practices to protect patient safety.
The policy also addresses broader drug supply issues, including those related to controlled substances, generic medications and on-patent drugs. The AMA opposes business practices that artificially create shortages, such as limitations on pharmacy procurement or restrictions on where patients can fill prescriptions, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.